Unicycive Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Net Loss Per Share (Tables)

Net Loss Per Share (Tables)

6 Months Ended

Jun. 30, 2023

Schedule of Basic and Diluted Net Income (Loss) Per Share

The following table sets forth the computation of basic and diluted net loss per share of common and preferred stock (in thousands, except share and per share data):

	Three Months Ended June 30,						Six Months Ended June 30,
	2022			2023			2022			2023
Numerator:
Net loss	$	(3,636	)	$	(3,838	)	$	(7,173	)	$	(18,413	)
Less: Deemed dividends on Series A-1 Preferred Stock		-			(603	)		-			(795	)
Net loss attributable to common shares, basic and diluted		(3,636	)		(4,441	)		(7,173	)		(19,208	)

Denominator:
Weighted-average shares outstanding used in computing net loss per share attributable to common stockholders, basic and diluted		15,028,689			15,234,570			15,024,581			15,233,503
Net loss per share attributable to common stockholders, basic and diluted	$	(0.24	)	$	(0.29	)	$	(0.48	)	$	(1.26	)

Schedule of Outstanding Shares of Potentially Dilutive Securities were Excluded from the Computation of Diluted Net Income (Loss) Per Share

The following outstanding shares of potentially dilutive securities were excluded from the computation of diluted net loss per share for the periods presented because including them would have been antidilutive:

	Three Months Ended June 30,				Six Months Ended June 30,
	2022		2023		2022		2023

Options to purchase common stock		1,177,104		1,334,309		1,177,104		1,334,309
Warrants to purchase common stock		4,784,193		4,784,193		4,784,193		4,784,193
Warrants to purchase convertible preferred stock		-		160,958,167		-		160,958,167
Total		5,961,297		167,076,669		5,961,297		167,076,669